Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss

Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

A dosing patent could add nearly five years of U.S. protection for a Rett syndrome treatment

Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”

3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop

Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33